The Morningstar Denmark Index has seen a 20.7% decline in 2025 and 38.4% in the past 12 months, making Danish stocks potentially undervalued. Companies like Coloplast, GN Store Nord, and Genmab are trading at significant discounts to their fair value estimates, particularly in the healthcare sector.

Novo Nordisk, Denmark’s largest company, has lost nearly 60% of its market value in the past year, driving down the Morningstar Denmark Index due to its 41% weighting. The company’s struggles in the weight-loss drug sector have led to job cuts and downward revisions in growth targets, impacting investor sentiment.

Denmark’s green energy industry, including companies like Orsted, has also faced setbacks, with shares down 41% year-to-date. Falling energy prices, competition from nuclear energy, and political shifts have contributed to the sector’s challenges. Orsted’s shares are trading at a 37% discount after an EUR 8.1 billion rights issue.

US-Denmark tensions, fueled by Trump’s interest in acquiring Greenland, add geopolitical risk to Danish stocks. While there is no direct targeting of Danish stocks, recent disputes and political undertones have impacted the equity market. Novo Nordisk’s heavy reliance on the US pharmaceutical market makes it particularly vulnerable to US policy changes.

Read more at Morningstar: Is Now a Good Time to Buy Danish Stocks?